Acquired Company

Context Therapeutics acquired CT-95 (formerly LNK101), a mesothelin x CD3 bispecific antibody, from Link Immunotherapeutics, Inc., on July 9, 2024, via asset purchase.

Context Therapeutics Inc. is a late-stage biopharmaceutical company headquartered in Boston, focused on pioneering innovative non-opioid therapies for chronic pain management. The company is at the forefront of addressing significant unmet medical needs with its robust pipeline of therapeutic candidates aimed at enhancing patient outcomes while prioritizing safety. By championing non-addictive treatment options, Context Therapeutics is positioned to play a critical role in reducing opioid dependency and transforming the landscape of pain management, establishing itself as a leader in the movement towards safer and more effective alternatives. Show more

Location: 2001 MARKET STREET, PHILADELPHIA, PA, UNITED STATES, 19103, Suite 200, Philadelphia, PA, 19103, USA | Website: https://www.contexttherapeutics.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

239.8M

52 Wk Range

$0.49 - $2.85

Previous Close

$2.47

Open

$2.43

Volume

4,282,357

Day Range

$2.43 - $2.85

Enterprise Value

150.1M

Cash

76.94M

Avg Qtr Burn

-6.579M

Insider Ownership

1.18%

Institutional Own.

75.67%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CT-95 Details Solid tumor/s	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTIM-76 Details Testicular cancer, Endometrial cancer, Ovarian cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CT-202 Details Cancer, solid tumor/s	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ONA-XR Details Metastatic breast cancer to brain, ER+/HER2- breast cancer, Breast cancer, Cancer, Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ONA-XR Details Breast cancer, Cancer, Solid tumor/s, Metastatic breast cancer to brain, ER+/HER2- breast cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ONA-XR Details Solid tumor/s, Cancer, Ovarian cancer, Endometrial cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.